At a record breaking ESC 2025 in Madrid, Spain (29 August-1 September 2025), with over 1,100 sessions showcasing practice-changing research, Lp(a) focused advances included new ESC/EAS guidance on Lp(a) as a cardiovascular risk-enhancing factor, together with new research on reduced need for lipoprotein apheresis with Lp(a) lowering therapy, latest trends in Lp(a) testing, patient advice […]
A new focused update of the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) dyslipidaemia guidelines, announced at the ESC 2025 congress, recommends that an elevated Lp(a) >50 mg/dL (>105 nmol/L) should be considered as a cardiovascular (CV) risk-enhancing factor in all adults, with higher Lp(a) levels associated with a greater increase in risk […]
Pelacarsen reduces the need for lipoprotein apheresis (LA) in patients with elevated Lp(a) and cardiovascular disease (CVD), according to results of the Phase 3 Lp(a)FRONTIERS APHERESIS trial carried out in Germany.
Approximately 15% of the Norwegian adult population had an Lp(a) test between 2000 and 2023, including 1.5% of the population over 18 years in 2023 (64,875 Lp(a) measurements). Tests were primarily requested by GPs, and a family history of premature cardiovascular disease (CVD) was the major motivation for testing.
A systematic review of Lp(a) reporting across Australia has shown significant heterogeneity, with many labs lacking access to on-site testing – something which is likely to contribute to increased testing costs, said researchers.
Getting an elevated Lp(a) test result encourages patients with coronary heart disease (CHD) to make more effort to reduce their overall risk of cardiovascular disease (CVD) and makes them want close relatives to get tested too. However, most are unaware that the Lp(a) level is inherited and cannot be modified by lifestyle, and they think […]
